Evidence map›Paper›PMID 38201623›Full record

ReviewCancers2023

TAMs and PD-1 Networking in Gastric Cancer: A Review of the Literature.

Melina Yerolatsite, Nanteznta Torounidou, Aristeidis Gogadis, Fani Kapoulitsa, Panagiotis Ntellas, Evangeli Lampri, Maria Tolia, Anna Batistatou, Konstantinos Katsanos, Davide Mauri

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Melina YerolatsiteDepartment of Medical Oncology, University of Ioannina, 45500 Ioannina, Greece.
Nanteznta TorounidouDepartment of Medical Oncology, University of Ioannina, 45500 Ioannina, Greece.
Aristeidis GogadisDepartment of Medical Oncology, University of Ioannina, 45500 Ioannina, Greece.
Fani KapoulitsaDepartment of Medical Oncology, University of Ioannina, 45500 Ioannina, Greece.
Panagiotis NtellasDepartment of Medical Oncology, University of Ioannina, 45500 Ioannina, Greece.
Evangeli LampriDepartment of Pathology, University of Ioannina, 45500 Ioannina, Greece.
Maria ToliaDepartment of Radiotherapy, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0001-5822-4363
Anna BatistatouDepartment of Pathology, University of Ioannina, 45500 Ioannina, Greece.
Konstantinos KatsanosDepartment of Gastroenterology, University of Ioannina, 45500 Ioannina, Greece.
Davide MauriDepartment of Medical Oncology, University of Ioannina, 45500 Ioannina, Greece.
University of Ioannina · GRUniversity of Crete · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric cancer (GC) is one of the most common and aggressive types of cancer. Immune checkpoint inhibitors (ICIs) have proven effective in treating various types of cancer. The use of ICIs in GC patients is currently an area of ongoing research. The tumor microenvironment (TME) also seems to play a crucial role in cancer progression. Tumor-associated macrophages (TAMs) are the most abundant population in the TME. TAMs are capable of displaying programmed cell death protein 1 (PD-1) on their surface and can form a ligand with programmed death ligand 1 (PD-L1), which is found on the surface of cancer cells. Therefore, it is expected that TAMs may significantly influence the immune response related to immune checkpoint inhibitors (ICIs). AIM OF THE STUDY: Understanding the role of TAMs and PD-1/PD-L1 networking in GC.

methodsA systematic review of published data was performed using MEDLINE (PubMed), Embase, and Cochrane databases. We retrieved articles investigating the co-existence of TAMs and PD-1 in GC and the prognosis of patients expressing high levels of PD-1+ TAMs.

resultsTen articles with a total of 2277 patients were included in the systematic review. The examined data suggest that the expression of PD-L1 has a positive correlation with the infiltration of TAMs and that patients who express high levels of PD-1+ TAMs may have a worse prognosis than those who express low levels of PD-1+ TAMs.

conclusionsTAMs play a pivotal role in the regulation of PD-1/PD-L1 networking and the progression of GC cells. Nevertheless, additional studies are needed to better define the role of TAMs and PD-1/PD-L1 networking in GC.

Indexed as

gastric cancerimmune checkpoint inhibitors (ICIs)PD-1/PD-L1tumor-associated macrophages (TAMs)tumor microenvironment (TME)

Identifiers

PMID38201623
PMCPMC10778110
OpenAlexW4390470929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.